In the Mix: 10 More Articles — May 28, 2026
This digest covers cannabis regulatory enforcement challenges 2026, highlighting DEA registration efforts and legal developments. It provides insights into market compliance and clinical implications. Clinicians should monitor these evolving regulations…
Cannabis Medicine in Family Practice: Evidence-Based Dosing Strategies from Endocannabinoid System Research
This article reviews evidence-based cannabis dosing strategies in family practice, emphasizing insights from endocannabinoid system research. Understanding these strategies helps clinicians optimize cannabis medicine use. Evidence-based cannabis dosing…
Why Higher THC Exposure Does Not Necessarily Mean Stronger THC Effects
THC blood levels vs effects is one of the most misunderstood concepts in cannabis medicine. A new study found that CBD increased THC exposure in the bloodstream after vaporized cannabis use. However, higher THC blood concentrations do not automatically…
THC and Alzheimer’s Agitation
THC for Alzheimer’s agitation is drawing attention after a randomized placebo-controlled dronabinol trial reported short-term reductions in agitation scores. The study is clinically meaningful because dementia-related agitation can be devastating for…
In the Mix: 3 More Articles — May 28, 2026
This post reviews mixed cannabis industry articles May 28 2026 below the clinical relevance threshold. It covers diverse topics including law enforcement and community news. The mixed cannabis industry articles May 28 2026 highlight the fragmented nature…
The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines
The DEA’s new cannabis registration system may quietly reshape American cannabinoid medicine. This policy shift could influence research, taxation, institutional acceptance, and physician participation far beyond the headlines. Here is what clinicians…
The First Cannabis Drug to Earn FDA Breakthrough Therapy Status for Pain`
The FDA has granted Breakthrough Therapy Designation to VER-01, a full-spectrum cannabis extract, after two Phase 3 RCTs showed significant pain reduction in patients with chronic low back pain. VER-01 outperformed opioids on both pain relief and…
SAMHSA’s 2026 Clinical Guidance for Physicians and Patients on Cannabis Use Disorder
SAMHSA released a formal 2026 advisory instructing primary care physicians to evaluate cannabis use based on clinical signs of harm, not simply patient use. Dr. Caplan breaks down what this federal guidance actually says, where current diagnostic tools…
CBD Increases Food Intake in Controlled Human Trial
This clinical trial on CBD appetite regulation reveals that cannabidiol increases food intake in healthy adults. Despite lower ghrelin levels, participants consumed more calories, challenging previous assumptions. These findings highlight the complexity…
Cannabis Use in Pregnancy Linked to Child Behavioral Outcomes: A Study on Autism Spectrum Disorder
Peripregnancy cannabis exposure child development is associated with behavioral and developmental challenges in young children. This includes those with autism spectrum disorder symptoms and those without. The study highlights the importance of avoiding…